Comprehensive Tumor Panel 270 Genes PDL1
Advanced Cancer Genetic Profiling for Personalized Treatment
The Comprehensive Tumor Panel 270 Genes PDL1 represents a cutting-edge approach to cancer diagnostics, providing comprehensive genomic analysis that goes beyond traditional testing methods. This sophisticated panel examines 270 carefully selected cancer-related genes while simultaneously assessing PDL1 expression levels, offering clinicians a complete molecular picture of a patient’s tumor biology.
What This Revolutionary Test Measures
Our comprehensive panel detects and analyzes multiple critical aspects of tumor genetics:
- 270 Cancer-Related Genes: Comprehensive coverage of oncogenes, tumor suppressor genes, and DNA repair genes across all major cancer pathways
- PDL1 Expression Status: Quantitative assessment of programmed death-ligand 1 protein levels, a key biomarker for immunotherapy response
- Genetic Mutations: Identification of somatic mutations including single nucleotide variants, insertions, deletions, and copy number variations
- Biomarker Detection: Analysis of predictive biomarkers that influence treatment selection and clinical outcomes
- Actionable Targets: Identification of specific genetic alterations that can be targeted with precision therapies
Who Should Consider This Advanced Genetic Testing
This comprehensive panel is particularly valuable for patients experiencing:
- Newly diagnosed solid tumors requiring comprehensive molecular profiling
- Advanced or metastatic cancers where treatment options are limited
- Cancers with unclear histology or unknown primary origin
- Treatment-resistant tumors requiring alternative therapeutic approaches
- Rare cancer types with limited standard treatment protocols
- Patients considering immunotherapy who need PDL1 status assessment
- Individuals with family cancer history suggesting hereditary predisposition
Transformative Benefits of Comprehensive Tumor Profiling
Choosing our Comprehensive Tumor Panel 270 Genes PDL1 offers multiple clinical advantages:
- Personalized Treatment Planning: Identify specific genetic alterations that respond to targeted therapies
- Immunotherapy Eligibility: Determine PDL1 status to assess potential response to immune checkpoint inhibitors
- Comprehensive Mutation Analysis: Single test covering multiple genetic alterations across critical cancer pathways
- Treatment Resistance Insights: Understand mechanisms behind treatment failure and identify alternative options
- Clinical Trial Matching: Identify eligibility for precision medicine trials based on specific genetic profiles
- Prognostic Information: Gain insights into disease progression and potential treatment outcomes
- Cost-Effective Approach: Comprehensive testing reduces need for multiple individual genetic tests
Understanding Your Test Results
Your comprehensive genetic report will provide detailed information in several key areas:
- Detected Mutations: Clear identification of specific genetic alterations found in your tumor sample
- Actionability Assessment: Classification of mutations based on clinical significance and available treatments
- PDL1 Expression Levels: Quantitative measurement indicating potential response to immunotherapy
- Therapeutic Recommendations: Evidence-based suggestions for targeted therapies and treatment approaches
- Clinical Trial Opportunities: Information about relevant clinical trials matching your genetic profile
- Interpretive Guidance: Clear explanations of complex genetic findings in clinically relevant context
All results are reviewed by our team of board-certified molecular pathologists and genetic specialists to ensure accurate interpretation and clinical relevance.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Comprehensive Tumor Panel 270 Genes PDL1 | $1234 USD | $1500 USD |
Nationwide Testing Accessibility
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network of certified laboratories ensures consistent quality and reliable results nationwide.
Take Control of Your Cancer Journey
Don’t leave your treatment decisions to chance. Our Comprehensive Tumor Panel 270 Genes PDL1 provides the molecular intelligence needed to make informed decisions about your cancer care. With advanced genetic insights and PDL1 status assessment, you and your healthcare team can develop a personalized treatment strategy tailored to your unique cancer profile.
Ready to unlock the power of precision oncology? Book your Comprehensive Tumor Panel 270 Genes PDL1 test today by calling our dedicated patient care team at +1(267) 388-9828 or schedule your appointment online. Take the first step toward personalized cancer care backed by comprehensive genetic intelligence.
